Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis
Status:
Terminated
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to determine whether a therapeutic strategy combining mitoxantrone
and interferon beta1b can delay disease progression of at least one point on EDSS scale in
patients with clinically very active relapsing-remitting multiple sclerosis.
Phase:
Phase 2
Details
Lead Sponsor:
Rennes University Hospital
Collaborators:
Bayer Farmades, Italy Wyeth is now a wholly owned subsidiary of Pfizer